← All decks
The first 25 slides, exactly as they appear. The full deck has 117 content slides.
Dermatology
Erythema Multiforme, Stevens–Johnson Syndrome, and Toxic Epidermal Necrolysis
Built from Dermatology, 5th Edition
What’s inside
3 sections · 117 slides
Overview
- Scope of this topic
- How this chapter is organised
Erythema Multiforme
A self-limited, often recurrent skin disease usually triggered by herpes simplex virus
- What erythema multiforme is
- Key features of erythema multiforme
- History of erythema multiforme
- Epidemiology of erythema multiforme
- What triggers erythema multiforme
- Precipitating factors in erythema multiforme
- Precipitating factors in erythema multiforme.
- Precipitating factors in erythema multiforme. (continued)
- Precipitating factors in erythema multiforme. (continued)
- How HSV triggers an EM lesion
- How HSV-associated EM lesions form
- Mycoplasma pneumoniae and other triggers
- Erythema multiforme lesions on the trunk
- Phenotypic variety of erythema multiforme lesions
- Atypical papular target lesions
- Where EM lesions appear
- Mucosal involvement in erythema multiforme major
- Mucosal and systemic features of EM
- Natural history of erythema multiforme
- Recurrence of erythema multiforme
- Histopathologic features of erythema multiforme
- Pathology of erythema multiforme
- Urticaria multiforme misdiagnosed as erythema multiforme
- Distinguishing EM from urticaria
- Comparison of urticaria and erythema multiforme.
- Erythema multiforme–like lesions in lupus and Sweet syndrome
- Other mimics of erythema multiforme
- Mycoplasma-induced rash and mucositis (MIRM)/RIME
- Key features of MIRM/RIME
- Key features of Mycoplasma pneumoniae-induced rash and mucositis (MIRM)/reactive infectious mucocutaneous eruption (RIME).
- Key features of Mycoplasma pneumoniae-induced rash and mucositis (MIRM)/reactive infectious mucocutaneous eruption (RIME). (continued)
- Treating erythema multiforme
- Preventing recurrent HSV-associated EM
- Summary: erythema multiforme
Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis
Two ends of one severe, drug-induced spectrum, defined by how much skin comes off
- What SJS and TEN are
- Key features of SJS and TEN
- History of SJS and TEN
- Comparing EM, SJS, and TEN
- Comparison of EM, SJS, and TEN: lesion type and precipitating factors (part 1 of Table 20.1)
- Comparison of EM, SJS, and TEN: distribution, mucosal, and systemic features (part 2 of Table 20.1)
- EM versus SJS/TEN: how they differ
- 1.2–6
- Risk factors for SJS and TEN
- SJS/TEN epidemiology and risk factors
- Stevens–Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN): epidemiology and risk factors.
- Stevens–Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN): epidemiology and risk factors. (continued)
- Mortality trends in SJS/TEN
- Drugs associated with SJS/TEN
- Medications most often implicated
- Medications most frequently associated with Stevens–Johnson syndrome and toxic epidermal necrolysis.
- Childhood Stevens–Johnson syndrome from trimethoprim–sulfamethoxazole
- Stevens–Johnson syndrome due to ipilimumab
- Pathogenesis: from drug exposure to immune attack
- Three ways a drug can form a neoantigen
- HLA and drug risk
- Immune cells and cytokines involved
- How keratinocytes die in SJS/TEN
- Proposed pathomechanisms of keratinocyte apoptosis in SJS/TEN
- Four death pathways that kill keratinocytes
- The Fas signalling pathway of apoptotic cell death
- Pathogenesis of SJS/TEN, step by step
- Clinical onset of SJS/TEN
- Early dusky macules of toxic epidermal necrolysis
- Clinical features of toxic epidermal necrolysis
- From macules to blisters: "wet cigarette paper"
- Classifying severity by surface area
- Spectrum of disease by surface area of epidermal detachment
- SJS/TEN overlap and early toxic epidermal necrolysis
- SJS/TEN overlap from trimethoprim–sulfamethoxazole
- Mucosal involvement in Stevens–Johnson syndrome
- Hemorrhagic crusting and mucosal involvement in TEN
- The wider picture of mucosal disease
- Toxic epidermal necrolysis due to an antimalarial drug
- Early Stevens–Johnson syndrome
- Distinguishing SJS from EM
- Predicting outcome in TEN
- SCORTEN: a severity-of-illness score
- SCORTEN prognostic factors
- SCORTEN score and mortality rate
- ABCD-10: an alternative mortality score
- Why patients with TEN die
- Long-term sequelae of toxic epidermal necrolysis
- Healing and long-term sequelae
- Histopathologic features of toxic epidermal necrolysis
- Early histopathologic changes in toxic epidermal necrolysis
- Pathology confirms the diagnosis
- Identifying the culprit drug
- Differential diagnosis of toxic epidermal necrolysis
- Differential diagnosis of toxic epidermal necrolysis.
- Differential diagnosis of toxic epidermal necrolysis. (continued)
- Differential diagnosis of toxic epidermal necrolysis. (continued)
- Approach to the patient with SJS or TEN
- Treatment principles for SJS/TEN
- Wound and skin care
- Eye, mouth, and genital care
- Systemic drug therapy: the evidence
- Facial toxic epidermal necrolysis before and after IVIg
- IVIg in SJS/TEN
- Evidence for and against SJS/TEN therapies
- A cautionary tale: thalidomide
- Long-term management
- Summary: Stevens–Johnson syndrome and TEN
- References
- References (continued)
- References (continued)
- References (continued)
- References (continued)
- References (continued)
- References (continued)
- References (continued)
- References (continued)
- References (continued)
- References (continued)
- References (continued)
- Dermatology, 5th Edition (2-Volume Set)